Newly-Listed Psoriasis Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation

Benzinga15:18 ET

Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price

Benzinga15:04 ET

Bio-Thera Biosimilar to J&J's Stelara Under FDA Review

Seeking Alpha13:06 ET

Check Out What Whales Are Doing With JNJ

Benzinga12:01 ET

Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial

BenzingaJul 23 14:55 ET

Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression

BenzingaJul 23 13:20 ET